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ABSTRACT 
 
Rationale: In response to blood vessel wall injury, aberrant proliferation of vascular smooth muscle cells 
causes pathologic remodelling. However, the controlling mechanisms are not completely understood.  
 
Objective: We recently showed that the human long non-coding RNA, SMILR, promotes vascular smooth  
muscle cells (vSMCs) proliferation by a hitherto unknown mechanism. Here, we assess the therapeutic 
potential of SMILR inhibition and detail the molecular mechanism of action.  
 
Methods and Results: We used deep RNA-sequencing of human saphenous vein smooth muscle cells 
stimulated with IL1α and PDGF-BB with SMILR-knockdown (siRNA) or -overexpression (lentivirus), to 
identify SMILR regulated genes. This revealed a SMILR-dependent network essential for cell-cycle 
progression. In particular, we found using the fluorescent ubiquitination-based cell cycle indicator viral 
system that SMILR regulates the late mitotic phase of the cell cycle and cytokinesis with SMILR knockdown 
resulting in ~10% increase in binucleated cells. SMILR-pulldowns further revealed its potential molecular 
mechanism, which involves an interaction with the mRNA of the late mitotic protein CENPF and the 
regulatory Staufen1 RNA-binding protein. SMILR and this downstream axis were also found to be activated 
in the human ex vivo vein graft pathological model and in primary human coronary artery smooth muscle 
cells and atherosclerotic plaques obtained at carotid endarterectomy. Finally, to assess the therapeutic 
potential of SMILR, we used a novel siRNA approach in the ex vivo vein graft model (within the 30 min 
clinical time frame that would occur between harvest and implant) to assess the reduction of proliferation 
by EdU incorporation. SMILR-knockdown led to a marked decrease in proliferation from ~29% in controls 
to ~5% with SMILR depletion. 
 
Conclusion: Collectively, we demonstrate that SMILR is a critical mediator of vascular smooth muscle cell 
proliferation via direct regulation of mitotic progression. Our data further reveals a potential SMILR-
targeting intervention to limit atherogenesis and adverse vascular remodelling. 
 
Keywords: 
Long non-coding RNA; vascular smooth muscle cells; cell cycle; proliferation; vascular remodelling. 
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Nonstandard Abbreviations and Acronyms: 
 
vSMCs  Vascular smooth muscle cells 
IL1-PDGF IL1-α and PDGF-ββ-induced 
lncRNA Long non-coding RNA 
RNA-seq RNA-sequencing 
PCA  Principal component analysis 
HSV  Human saphenous vein 
HSVSMCs Humans saphenous vein derived smooth muscle cells 
HCASMCs Human coronary smooth muscle cells 
siRNA   Small interfering RNA 
LNT  Lentivirus 
GO   Gene ontology 
FUCCI  Fluorescence Ubiquitin Cell Cycle Indicator 
AurKB  Aurora kinase N 
RAP  RNA antisense pulldown 
STAU1  Staufen 1 RNA binding protein 
FISH  Fluorescence in situ hybridisation 
 
 
INTRODUCTION 
 
Aberrant proliferation of vascular smooth muscle cells (vSMCs) is a common and functionally 
important mechanism that impacts on the pathogenesis of many vascular diseases, including intimal 
thickening associated with remodelling of intra-vascular stents, coronary artery bypass graft failure, 
atherosclerosis and aortic aneurysm formation. In particular, vSMC proliferation is promoted by the 
injurious microenvironment, partly through the increased exposure of vSMC to inflammatory cytokines 
and growth factors such as interleukin-1 (IL-1) and platelet derived growth factor (PDGF), respectively. 
These often act in synergy to promote a proliferative phenotype with associated activation of critical gene 
networks, such as metalloproteinases 1-4. Clinically, targeting vSMC proliferation is exceptionally effective 
at reducing adverse vascular remodelling following balloon angioplasty and vessel stenting, evidenced by 
extensive research and development of anti-proliferative drug eluting stent technologies 5, 6. For iatrogenic 
vascular injury, pathogenic SMC proliferation causes intimal hyperplasia and luminal narrowing of blood 
vessels in the setting of vascular stenting or vein graft failure 2, 7.  In more complex settings, such as 
atherosclerosis, vSMC proliferation is central to the accumulation of large numbers of plaque-derived 
vSMC that not only contribute to the atherogenic process itself but can also confer plaque stabilisation 8, 9. 
Despite context-dependent heterogeneity in vSMC pathobiology, the underlying activation of vSMC 
proliferation is a central phenotype to the progression of vessel wall dysfunction. It is therefore imperative 
to further understand the molecular mechanisms that govern vSMC proliferation pathways in order to 
advance innovative therapies.  
 
Recently, robust evidence has revealed that non-coding RNAs may play a vital role in the regulation 
of tissue homeostasis, including cardiovascular homeostasis, and hence pathophysiological conditions 10. 
Mammalian genomes are pervasively transcribed to produce thousands of long non-coding RNAs 
(lncRNAs). LncRNAs are widely involved in physiological and pathological processes such as cancer 11, 
autoimmune diseases 12 and cardiac disease 13. LncRNA can exert their function via a broad range of 
activities including, but not limited to, chromatin remodelling, formation of nuclear bodies, and activities 
as scaffolds and guides 14. Previous findings have suggested that a substantial proportion of lncRNAs reside 
within, or are dynamically shuttled to, the cytoplasm in order to regulate mRNA stability, protein 
translation, microRNA availability and impact upon protein modifications 15. Such RNA-based regulation 
generally relies on lncRNA interactions with RNA binding proteins 16.  We previously identified the 
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lncRNA SMILR by RNAseq of human vSMCs following activation by IL-1  and PDGF-ββ signalling 17. 
SMILR is an intergenic and poorly conserved lncRNA that consists of only a single 3-exon polyadenylated 
transcript that is vSMC-enriched, and its knockdown by RNA interference blocked IL-1  and PDGF-ββ-
induced (IL1-PDGF) vSMC proliferation 17. Thus, we reasoned that identifying the downstream targets and 
binding partners of SMILR would reveal the specific mechanism by which it regulates vSMC proliferation 
and hence provide a novel therapeutic target for preventing adverse vascular remodelling. 
 
 
 
METHODS 
 
The authors declare that all supporting data and materials are available within the article [and its online 
supplementary files] and available from the corresponding author upon reasonable request. All RNA 
sequencing data have been made deposited in the Gene Expression Omnibus (GEO) repository, study 
number GSE120521 for the atherosclerosis RNAseq and GSE117608 for SMILR RNAseq. 
 
Expanded information about materials and methods are available in Online Supplementary Material. 
 
Declaration of Helsinki. 
All studies comply with the Declaration of Helsinki, that the locally appointed ethics committee has 
approved the research protocol and that informed consent has been obtained from the subjects. 
 
Primary human saphenous vein smooth muscle cells (HSVSMC) were isolated via explant technique from 
consented patients and cultured as previously described 17. All procedures had local ethical approval 
(15/ES/0094). HSVSMC from passage 3 to 5 were used for this study and cells were synchronised in 
DMEM containing 0.2% FBS for 48 h prior to experimentation. Modulation of SMILR expression was 
performed through the utilisation of dsiRNA or SMILR lentivirus with appropriate controls and their effect 
on the genome was assessed via RNA sequencing and confirmed through subsequent qRT-PCR validation. 
All qRT-PCR data was analysed via the 2-ΔΔCt method 18. This method utilises a house keeping gene and 
ubiquitin C (UBC) was selected as a housekeeping gene due to its stability across all groups and conditions 
studied. Data is graphed as relative quantification normalized to the UBC housekeeping gene 18.  
 
Assessment of siRNA-SMILR on SMC cell cycle was performed via FUCCI-FACs analysis and confocal 
imaging for the % of binucleated cells. SiRNA targeting AURKB was used as a positive control in these 
studies as previously described 19, 20. 
 
To evaluate binding partners of SMILR, antisense SMILR or GFP probes were designed. For each pulldown 
experiment either 5 GFP or 5 SMILR probes were utilised to capture bound RNA. Prior to RNA extraction, 
RNA was spiked with 75ng of total C. elegans RNA and AMA1 used as a reference gene as previously 
described 21. qRT-PCR was utilised to assess RNA expression.  
 
To assess if SMILR exhibited any venous/arterial differences in expression or function, human coronary 
artery smooth muscle cells (HCASMC) were utilise and cultured under the same conditions as HSVSMCs. 
Stimulation of these cells was performed under basal and IL1/PDGF-BB stimulated conditions as described 
in Ballantyne et al 17 and assessment of the effect of siRNA-SMILR on HCASMC proliferation (Edu-
FACS), binucleation (confocal imaging) and  downstream target expression (qRT-PCR) was performed.  
To address if SMILR exhibited any protein binding partners, SMILR protein pulldowns were performed 
utilising streptavidin magnetic beads to capture the biotinylated RNA target and any bound proteins from 
stimulated smooth muscle cells. Mass spectrometric analysis was utilised to identify proteins for subsequent 
downstream analysis and validation. Anti-Stau1 pulldowns were utilised as validation with appropriate igG 
control to confirm SMILR and other RNA target binding by qRT-PCR.  
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Similar to Ballantyne et. al.17 patients with symptomatic carotid artery stenosis scheduled to undergo carotid 
endarterectomy were recruited from neurovascular clinics at the Royal Infirmary of Edinburgh to undergo 
separate [18F]-fluoride and [18F]- fluorodeoxyglucose ([18F]-FDG) positron emission tomography 
combined with computed tomography (CT) scans. Regions of stable and unstable plaque were denoted by 
low and high tracer uptake respectively and appropriately dissected. RNA sequencing was performed to 
assess transcriptomic differences between plaque sections and SMILR expression assessed via qRT-PCR. 
In situ hybridisation was utilised to visualise the localisation of SMILR within the plaque regions.  
 
To assess the potential clinical utilisation of siSMILR, segments of human saphenous vein obtained from 
consented patients undergoing bypass surgery were pinned down with minutien pins on a Sylgard coated 
dissection dish with the luminal surface facing upward for 0, 7 or 14 days with media refreshed every 2 
days. At day 0 and after 7 and 14 days of culture, the vein segments were washed in PBS and snap frozen 
for subsequent RNA extraction or fixed in 4% PFA for histology. Proliferation of segments was assessed 
through the utilisation of Click-iT® EdU Alexa Fluor® 488 In Vivo Imaging Kit. Expression levels of 
SMILR and target RNA were assessed through qRT-PCR analysis. For siRNA transfections HSV segments 
cut in equal pieces of approximately 1 cm2 were bathed in PBS containing 25 μM siSMILR and scrambled 
siRNA control for 30 minutes in 24-well plate. After 30 minutes of incubation, the vein segments were 
washed with PBS and pinned down as described above. To confirm siRNA transfection, cy3 tagged SMILR 
was transfected and visualised along with DAPI and αSMA co staining via confocal imaging. 
   
Samples of ≥n=5 were subjected to Shapiro-Wilk test to assess normal distribution followed by student t 
test or ANOVA. Normal distribution cannot be determined on small samples sizes and samples with n<5 
were assumed to be not normally distributed and subjected to Iman and Conover non parametric ranking 
followed by students t test or ANOVA. Statistical significance P<0.05 under all conditions. 
 
 
 
RESULTS 
 
Manipulation of SMILR expression identifies a target cell cycle network in HSVSMCs. 
 
SMILR depletion and overexpression was previously shown to decrease and increase, respectively, 
proliferation induced by stimulation of HSVSMCs with IL1-PDGF 17. However, no characterisation of the 
mechanisms of regulation of SMILR by IL1-PDGF was described. Accordingly, we sought to identify the 
potential transcription factor binding sites within the promoter region of SMILR (Supplemental Figure IA). 
Within the 2000bp upstream of SMILR’s transcription start site, we identified binding sites for transcription 
factors that are activated by IL1 and/or PDGF-BB including: NF-KB, CEBP, ETS1, AP1, NFAT, IRF8, 
MYB, and AML (Supplemental Figure IB). Of the commercially available transcription factor inhibitors, 
we analysed the subsequent effects on SMILR expression following IL1-PDGF stimulation. This identified 
that the up-regulation of SMILR following IL1-PDGF stimulation may, in part, be due to activation of NF-
KB (Supplemental Figure IC and controls in ID).  Interestingly, SMILR overexpression does not trigger 
quiesced HSVSMCs to proliferate in the absence of IL1-PDGF stimulation (Supplemental Figure II). 
Therefore, to further determine the downstream effects of manipulation of SMILR levels on proliferation, 
RNA-seq was performed on stimulated HSVSMCs exposed to either SMILR depletion via siRNA 
(siSMILR) or overexpression via lentivirus (SMILR LNT) treatment to identify a downstream SMILR-
dependent transcriptome (Figure 1A).  
 
 Quantification of miR-146a, -221 and -222 by qRT-PCR confirmed activation of the IL1 and 
PDGF signalling pathways, respectively (Supplemental Figure III) 22, 23. Alterations in SMILR expression 
levels were validated by qPCR (Figure 1B).  Considering a fold change ≥ 1.5 and an adjusted FDR p < 
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0.05, 523 (334 downregulated and 189 upregulated) and 183 (126 upregulated and 57 down-regulated) 
transcripts were significantly differentially expressed following knockdown or overexpression, respectively 
(Figure 1C). As we observe opposing effects on proliferation with SMILR knockdown and overexpression, 
we focused on the transcripts that were dysregulated in opposing levels. This revealed 68 transcripts (Figure 
1C and D) indicating that such an approach might be powerful in identifying a distinct SMILR-targeted 
biological interactome. This set of SMILR-regulated genes was enriched for cell division-related and 
nucleosome assembly Gene Ontology (GO) terms (Figure 1E). Interestingly, analysis by STRING 24 
identified that 59% (n=40 of 68 genes) of the overlapping genes were associated with a single network 
involved in progression through the cell cycle, primarily the mitotic phase (Figure 1F). The top 20 genes 
identified by RNAseq that were differentially regulated genes by SMILR (Supplemental Figure IV) were 
selected for further validation in 3 different patient saphenous vein derived smooth muscle cells by qRT-
PCR. We observed consistent and robust opposing regulation of the network following SMILR depletion 
and overexpression in HSVSMCs stimulated with IL1-PDGF (Figure 1G,H). In agreement with the absence 
of proliferation phenotype after SMILR overexpression in non-stimulated quiescent conditions, SMILR 
overexpression in non-stimulated quiescent HSVSMCs did not result in transcription changes of the 
identified network (Supplemental Figure IIB). Collectively, these data suggest that SMILR mechanistically 
targets the vSMC cell cycle in response to IL1-PDGF stimulation. 
 
Manipulation of SMILR expression effects cell cycle progression in vSMC. 
 
Next, we functionally assessed SMILR’s ability to directly target cell cycle progression in 
HSVSMCs. First, we utilised the Fluorescence Ubiquitin Cell Cycle Indicator (FUCCI) viral system as well 
as flow cytometric analysis to track the cell cycle in synchronised HSVSMCs stimulated with IL1-PDGF 
for 96 hours with and without SMILR knockdown. Following FUCCI viral infection, cells in G0/G1 and 
S/G2/early M cell cycle phases express mCherry and mAzami-Green (mAG), respectively 25. Figure 2A 
represents the colour change predicted in cycling cells, dependent on the relative stage of cell cycle - red 
(G1), yellow/orange (G1/S) green (G2/early M), or colourless (late M/G0) fluorescence.   Aurora kinase B 
(AurKB), a well-known cell cycle and mitotic mediator, was used as a positive control. Notably, it is also 
one of SMILR’s downstream targets in the interactome (Figure 1F). Consistent with previous findings 
showing IL1-PDGF stimulation only promotes 30% of quiescent cells to proliferate 17, ~60% of the FUCCI-
infected HSVSMCs stimulated with IL1-PDGF were found to be colourless under control conditions 
(Figure 2B and C). Effective knockdown of AurKB in the HSVSMCs (4 ± 0.48 fold reduction compared to 
control, Supplemental Figure V) resulted in a cell cycle defect with a decrease in the G1 phase (p < 0.05) 
and concurrent increase in M/G0 phase (p < 0.05; Figure 2B and C). Analysis on FUCCI-infected cells also 
revealed a clear defect in the G1 phase and increase in the late M/G0 phase of the cell cycle following 
treatment with siSMILR, thereby phenocopying the effect of AurKB knockdown (Figure 2C). A hallmark 
of such a mitotic phase defect is the inability to correctly segregate daughter from mother cells during 
cytokinesis, resulting in cellular binucleation 26, which was evident in both FUCCI-infected cells treated 
with siAurKB and siSMILR (Figure 2D). Accordingly, cells treated with siSMILR and siAURKB were 
stained with DAPI and phalloidin and assessed for binucleation via fluorescent microscopy (Figure 2E and 
F). This revealed an increase in the percentage of binucleated cells from 7.2 ± 0.6% and 9.1 ± 0.3% in non-
transfected and siControls, respectively, to 17.1 ± 0.4% following SMILR depletion (p < 0.05), and a similar 
phenotype was observed in siAurKB-treated cells (20.3 ± 1.6% binucleation) (Figure 2G). Importantly, 
siRNA treatment had no significant effect on apoptosis with any of the siRNA-based treatments (Figure 
2H). Taken together, these data implicate a function for SMILR in regulating the late mitotic phase of cell 
cycle in vSMCs.  
 
SMILR directly targets CENPF in the cell cycle network. 
 
With both overexpression17 and knockdown (Supplemental Figure IV) approaches affecting SMILR 
expression levels predominantly in the cytoplasmic fraction, we therefore reasoned that SMILR could 
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directly regulate the identified affected genes by binding to the mRNA in the cytoplasm. We used a database 
of predicted lncRNA-RNA interactions by Terai et al 27 and considered the top100 genes predicted to 
interact with SMILR based on SumEnergy (Supplemental Table I). These genes were analysed in terms of 
expression level in stimulated vSMC, differential expression in SMILR depleted or SMILR overexpressed 
conditions, as well as differential expression upon stimulation with IL1-PDGF (see filtering details in 
Supplementary methods and summary in Supplemental Table I).  This revealed that CENPF, a mitotic 
centromere protein, was the highest ranked mRNA predicted to interact with SMILR (minimum and sum 
energy of -35 and -2631 kcal/mol, respectively, Supplemental Table I). The predicted interacting base pair 
region of the SMILR/CENPF mRNA interaction extends across 51 base pairs (39-90) within the sequence 
of SMILR and 58 base pairs (3291-3349) within the coding sequence of CENPF transcript (Supplemental 
Figure VII). We used RNA antisense pulldown (RAP) followed by qRT-PCR to confirm this predicted 
interaction. Two sets (5 even and 5 odd) of 3′-biotinylated DNA capture oligonucleotides were designed to 
hybridise specifically to SMILR (see Supplementary Methods) 28, 29. One set of five GFP-specific 3′-
biotinylated DNA capture oligonucleotides were also used as a negative control.  A schematic overview of 
the experimental design is provided in Figure 3A. The relative enrichment of SMILR and the CENPF 
mRNA present in both the SMILR-even and -odd pools were calculated with respect to the GFP pool, which 
was used as background reference. We observed a 3-fold and 4-fold enrichment of SMILR with the even 
and odd probes, respectively. CENPF transcript was also co-enriched by 13-fold and 7-fold in the even and 
odd SMILR pulldowns, respectively, thereby independently validating the predicted interaction between 
SMILR and CENPF mRNA. Importantly, MKI67 mRNA another downstream target within the SMILR-
dependent cell cycle network was assessed in the even and odd SMILR pulldowns and found to not to be 
enriched – suggesting specificity for a SMILR: CENPF mRNA interaction within the interactome (Figure 
3B). Additionally, in agreement with the RNAseq data, SMILR depletion and overexpression led to a down- 
and upregulation of CENPF transcript levels, respectively (Figure 3C and D). While having no effect on 
apoptosis, CENPF depletion (Supplemental Figure VIII) resulted in a significant decrease in EdU 
incorporation (Figure 3E-F). Additionally, similar to previous findings 30, 31, CENPF depletion resulted in 
an increase in the percentage of binucleated cells (12.5 ± 1.2%) comparable to SMILR knockdown (13.7 ± 
2.2%), which was significantly greater than that observed under control conditions (6.0 ± 2.0%, p < 0.05, 
Figure 3G-H). Importantly, knockdown of CENPF also phenotypically mimics the effects of SMILR 
knockdown on key genes within the cell cycle network (Figure 3I). Thus, these data support the concept 
that SMILR positively targets CENPF mRNA which is critical for vSMC proliferation.  
 
To further examine the temporal involvement of SMILR and CENPF transcripts in promoting IL1-
PDGF induced proliferation, time course experiments were employed and show that SMILR expression is 
significantly upregulated prior to significant EdU+ incorporation and CENPF mRNA expression is detected 
(Supplemental Figure IX). Taken together, this suggests that SMILR is required at the early stages of IL1-
PDGF stimulation to promote the induction of proliferation and mitotic progression.  
 
The SMILR:CENPF RNA interaction is regulated by Staufen1. 
 
RNAs, including lncRNAs, have been found to occasionally contain structural motifs that can 
interact with other RNAs to form functional RNA-RNA hybrids, which can then recruit proteins that 
regulate their function or stability 32. Accordingly, to understand whether the function of SMILR/CENPF 
RNA hybrid is dependent on a RNA:protein binding interaction, we performed pulldowns utilising 3’- 
desthiobiotin-labelled full length SMILR and protein lysates from IL1 PDGF stimulated HSVSMCs 
(Figure 4A). Mass spectrometry identified 14 potential SMILR-binding proteins (Figure 4B). The RNA 
binding protein staufen1 (STAU1), known to be involved in mRNA decay and binds lncRNA and mRNA 
hybrids 33, was clearly enriched in SMILR pulldowns when compared to beads alone or control 3’- 
desthiobiotin-labelled full length GFP pulldowns  (Supplemental Figure X). Moreover, previous reports 
have suggested that STAU1 is involved in checkpoint decisions in G2 and/or G2/M transitions, which 
intersects with the cell cycle defects observed with siSMILR 34. Hence, STAU1 appears to be a prime 
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candidate partner for SMILR’s mechanism of action. Immunoprecipitation of STAU1 from HSVSMC 
lysates stimulated with IL1PDGF followed by qRT-PCR revealed enrichment of SMILR by 2.8 ± 1 fold 
(p < 0.05) when compared to IgG controls (Figure 4C), validating the mass spectrometry results. 
Additionally, we found that STAU1 is likely to bind to SMILR within the first half of its sequence, which 
as mentioned above, is the predicted interaction site with CENPF (Supplemental Figure VII and XI). We 
also identified co-enrichment of CENPF in the STAU1 pulldowns by 5.0 ± 2.2 fold (p < 0.05; Figure 4C). 
To explore the involvement of STAU1 in controlling the proliferative phenotype mediated by SMILR and 
CENPF, we knocked down STAU1 using dsiRNA, and revealed an increase of SMILR and CENPF mRNA 
by 3.3 ± 0.9 fold and 3.0 ± 1.1 fold, respectively (Figure 4D).  We accordingly sought to further examine 
the effect of STAU1 knockdown on the SMILR downstream targets. Analysis of the same 20 targets 
described in Figure 1, which are down- and upregulated following SMILR knockdown and overexpression, 
revealed that 7 of these genes were significantly upregulated with STAU1 knockdown (Figure 4E). Using 
RNA FISH, we were also able to examine the co-localisation of SMILR and CENPF with STAU1 
knockdown (Figure 4F).  This revealed that, when compared to control conditions, SMILR/CENPF 
transcript co-localisation is not dependent on STAU1 expression, and that there appears to be increased 
SMILR/CENPF co-localisation events with STAU1 KD (Figure 4F).  Collectively, these data suggests that 
once SMILR expression is upregulated in IL1 PDGF conditions, it is able to bind to CENPF mRNA. This 
may subsequently counteract STAU1-mediated regulation thereby culminating in a proliferative 
environment and cell cycle progression in vSMCs. 
 
SMILR and the targeted cell cycle network are activated in atherosclerosis and ex vivo vein model of human 
saphenous vein. 
 
Despite context-dependent heterogeneity in vSMC pathobiology, defects in SMC cell cycle and 
hence proliferation, are hallmarks of vascular pathologies including atherosclerosis and neointimal 
hyperplasia associated with vein graft disease 3, 4, 9. As SMILR is poorly-conserved, we are limited to human 
disease and not animal models to study disease association and causality. To interrogate the 
SMILR:CENPF:STAU1 interaction in human atherosclerosis, we performed an RNAseq on relatively 
stable and unstable regions dissected from fresh human carotid plaques obtained at carotid endarterectomy 
in symptomatic patients. Although classified as “stable” these plaques may still contain regions of 
instability. This is demonstrated by ex vivo 18F- sodium fluoride imaging of explanted plaques which was 
utilised to confirm the appropriate segregation by regions of relatively more unstable versus stable plaque, 
where increased uptake of the radiotracer 35 was more apparent in “unstable” dissections and less so in the 
“stable” regions (Figure 5A). Importantly, Principal Component Analysis (PCA) of the RNAseq showed a 
clear clustering of the distinct regions separately, and not clustering together within each patient sample 
(Figure 5B). The differential expression analysis confirmed the changes of protein coding genes linked with 
plaque instability, including those associated with inflammation, matrix remodelling, and calcification 
(Supplemental Figure XII). SMILR expression was upregulated in all unstable plaque samples assessed by 
qRT-PCR (Figure 5C). Additionally, SMILR was detected using in situ hybridisation with varying intensity 
across all carotid atherosclerotic plaques from symptomatic patients (Figure D, Supplemental Figure XIII).  
STAU1 pulldowns in whole carotid plaques also further revealed an interaction with SMILR with a 2-fold 
enrichment compared to IgG controls (p<0.01) (Figure 5E). Remarkably, we also observed that 32 of the 
40 SMILR-dependent cell cycle interactome were also upregulated within the unstable plaques compared 
to stable, including CENPF (Figure 5F and G). Collectively, these data suggest that the SMILR/CENPF-
STAU1 axis is activated in unstable atherosclerosis. 
 
With arterial and venous smooth muscle cells differing significantly, we sought to further 
investigate the role of SMILR in relation to atherosclerosis by validating its mode of action in human 
coronary artery smooth muscle cells (HCASMCs). Firstly, we confirmed incorporation of EdU in 
HCASMCs stimulated with IL1-PDGF. This significantly upregulated proliferation, although as previously 
described (17, Figure 6A and B), the proliferative capacity of HCASMCs are significantly less than that 
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observed in the HSVSMCs. Nevertheless, with IL1-PDGF induced proliferation in the HCASMCs, we also 
identified by qRT-PCR significant increases in SMILR, CENPF, MKI67, AURKB, and CDC20 transcripts 
(Figure 6C and D). Importantly and similar to that observed in the HSVSMCs, knockdown of SMILR and 
CENPF in HCASMCs (Supplemental Figure XIV) resulted in reduction in proliferation (Figure 6E and F). 
Taken together, this suggests that although arterial and venous smooth muscle cells differ significantly, 
SMILR’s mechanism of action remains consistent.  
 
We also assessed the SMILR: CENPF axis in the context of vSMC proliferation associated with 
vein graft disease. Hereto, we used an ex vivo human saphenous vein (HSV) model 36, 37, which is associated 
with time-dependent SMC proliferation, migration and formation of neointima over 14 days in culture 
(Figure 7A) 38. We first validated this approach by monitoring EdU incorporation at 0, 7, and 14 days and 
found significant increases (Figure 7B and C). Thus, we hypothesised that SMILR expression may be 
regulated during the culture period. Accordingly, saphenous veins were cultured for 0, 7 or 14 days and the 
expression of SMILR, CENPF and the downstream cell cycle associated targets assessed by qRT-PCR. 
When compared to day 0 control, SMILR expression was increased 28 ± 13 (p < 0.05) and 53 ± 19 fold (p 
< 0.01), respectively, at day 7 and 14 (Figure 7D). We also identified a time-dependent increase in CENPF 
expression to 8 ± 1 fold (p < 0.05) at day 7 and 19 ± 7 fold (p < 0.05) at day 14 (Figure 7E). Similar to the 
qRT-PCR data obtained in Figure 6E, we are able to detect using immunohistochemistry increases in 
CENPF positive cells in the medial layer from 30% at day 0 to 51% at day 7 (Supplemental Figure XV). 
Concordantly, expression of other SMILR downstream targets within the cell cycle network, namely AurKB, 
BUB1B, MKI67 and CDC20, were upregulated at day 7 (22 ± 8, 11 ± 3, 22 ± 8 and 18 ± 7 fold change, 
respectively) and day 14 (41 ± 14, 34 ± 14, 75 ± 29 and 50 ± 31 fold change, respectively) (Supplemental 
Figure XVI). Overall, these data suggests that SMILR expression and its downstream network has a strong 
association with pathological remodelling in human ex vivo vein grafts.  
 
We then sought to manipulate SMILR expression in the ex vivo saphenous vein graft to assess the 
clinical relevance and therapeutic potential. We therefore used a novel siRNA approach within the 
clinically-relevant time window of an initial 30 minutes (clinical window from harvesting of the saphenous 
vein to grafting) prior to culture in which to attempt to knockdown SMILR. Cy3-tagged siSMILR was first 
used to visualise the successful infiltration of the siRNA into the vein (Figure 7F). Due to the limitations of 
the longevity of siRNA chemistry, by day 14 the siSMILR effects were found to be diminished 
(Supplemental Figure XVII). In veins with siRNA intervention leading to a significant decrease in SMILR 
levels assessed at Day 7 (Figure 7G), we also observed significant decreases in CENPF and MKI67 mRNA 
expression (Figure 7H and I). Finally, quantified proliferation by EdU incorporation in the cultured vein 
revealed a strong reduction from 28.7 ± 5.3 % EdU +ve/DAPI +ve nuclei in control conditions to 5.2 ± 2.6 
% with SMILR knockdown (Figure 7J and K, p < 0.01).  
 
 
 
DISCUSSION 
 
Aberrant growth of vSMCs is a common and functionally important mechanism, which may 
ultimately contribute to the etiology of numerous cardiovascular diseases 4. Although the general 
mechanism of cell-cycle regulation are well established 39, cell-enriched regulators such as lncRNA are not 
at all well defined in terms of expression, association and mechanism, which is crucial for the successful 
development of targeted therapeutics and improved knowledge of how the human transcriptome can impact 
physiological and pathological pathways. Here, we identify the mechanism and downstream network of the 
vSMC-enriched human lncRNA, SMILR, and demonstrate its therapeutic potential in the ex vivo HSV 
model (Figure 7). This has the potential to not only enhance our understanding of atherogenesis, neointimal 
hyperplasia and plaque formation, but also provides a clear therapeutic target for future investigation in a 
broad range of cardiovascular diseases. 
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The human genome contains a wide range of lncRNAs that are dynamically expressed in a temporal 
and cell specific manner. These lncRNAs can influence the level and spatial distribution of many proteins 
and mRNAs in order to control key aspects of cellular function. LncRNAs have previously been shown to 
modulate cell-cycle, primarily in cancer cell lines 40, 41. Additionally, lncRNAs, such as smooth muscle and 
endothelial cell enriched migration/differentiation-associated lncRNA (SENCR) and myocardin-induced 
smooth muscle lncRNA, inducer of differentiation (MYOSLID), have also been previously shown to be 
influential in cardiovascular diseases and essential in controlling the phenotypic switching of VSMCs to 
maintain their contractile phenotype (42, 43). More recently, the role of MEG3 in patients with pulmonary 
arterial hypertension was examined which revealed significantly reduced MEG3 expression levels in 
patients compared to healthy controls 44. In vitro siRNA silencing of MEG3 resulted in increased SMC 
proliferation and migration while mechanistic investigation revealed that MEG3 regulates the p53 pathway 
in PASMCs 45.  Although several lncRNAs have been identified that control key aspects of SMC and EC 
function, very little is known about their role in atherosclerosis. A key atherosclerotic lncRNA is ANRIL, 
which was identified via GWAS studies, in which several SNPs located within this lncRNA were associated 
with atherosclerosis. It was later identified that ANRIL regulates gene expression epigenetically through 
recruiting repressive components of the polycomb complexes 1 and 2 to ANRIL-target gene promoters via 
Alu-repeats 46.  
 
Here, we showed that SMILR specifically targets the late mitotic pathway in proliferating 
HSVSMCs and interacts with CENPF mRNA and STAU1. Two recent studies have demonstrated that the 
lncRNAs, SNHG5 and TINCR, counteract STAU1-mediated decay to promote the stabilisation of specific 
mRNAs to control tumour cell survival in colorectal cancer and somatic tissue differentiation, respectively 
29, 47. Similar to TINCR and its target mRNA PGLYRP3, SMILR’s interaction with CENPF mRNA appears 
to occur independent of STAU1 protein interaction as revealed by RNA-FISH.  Although we see up-
regulation of both CENPF mRNA and SMILR with STAU1 knockdown we cannot exclusively conclude 
whether STAU1’s interaction with SMILR: CENPF mRNA is regulating CENPF at a post-transcriptional 
and/or post-translational stage. Additionally, STAU1 may not only affect the levels of CENPF at an RNA 
and/or protein levels but also regulate its sub-cellular localisation since STAU1 has been found to be 
involved in mRNA transport and localisation to mediate further translation48.  
 
Whether the SMILR/CENPF interaction is dependent on base complementarity and/or secondary 
structure is a key future scientific question as the secondary structure of SMILR may be crucial for its 
localisation, downstream interactions, and hence function 49-51. Also, other mRNAs might be regulated by 
SMILR and STAU1 and sequencing of associated mRNAs may further provide a comprehensive network 
of interactions in proliferating vSMCs.  
 
Consistent with our findings, previous studies have indicated that STAU1 primarily binds to protein 
coding mRNAs of key mediators of cell cycle and that STAU1 expression and function necessarily 
fluctuates throughout the cell cycle, being highest during the S-phase and rapidly decreasing during mitotic 
progression 34. Additionally, STAU1 overexpression affects mitotic entry and impairs proliferation of 
transformed cells, therefore highlighting STAU1-function must be inhibited in a temporally dependent 
manner during the cell cycle for proper mitotic progression 34. With STAU1 being a ubiquitously expressed 
and a multi-functional protein, lncRNAs may be crucial for providing its cell-specific function and 
accordingly mediate cell-specific phenotypes. This may also be the case for CENPF, which is also 
ubiquitously expressed and shown to be multi-functional to control mitotic control, transcriptional 
regulation, and muscle cell differentiation 52. Intriguingly, increased levels of CENPF have also been 
previously associated with increased proliferation in malignant conditions 31 and associated with a poor 
prognosis in human cancers 53, 54.  However, the mechanism by which increased CENPF results in increased 
proliferation is not entirely understood. One possibility is that the role of CENPF in assembling kinetochore 
structures required for correct chromosome alignment and separation during mitosis is a rate-limiting step 
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for mitotic progression. Taken together, our study therefore suggests that SMILR may provide such a critical 
cell-specific regulation of STAU1 and CENPF function in human vSMCS to trigger cell cycle progression 
and proliferation. Further studies are required to dissect mechanistically the consequence of CENPF mRNA 
regulation by SMILR. Particularly CENPF’s mRNA stability, transport, and translation as well as the 
intersection of this with the mitotic phenotype that we observe when SMILR levels are reduced. 
 
SMILR was previously suggested to function, at least in part, by regulating its neighbouring gene, 
HAS217, although HAS2 is located ≈750kb from SMILR. However, we showed using RNAseq that HAS2 
is downregulated with SMILR knockdown but was not affected by SMILR overexpression, confirming 
previous findings 17.  We also demonstrated the proliferative effects of SMILR occur in the cytoplasmic 
fraction since the siRNA approach used selectively blocked cytoplasmic SMILR expression and would 
therefore unlikely involve a direct targeting of the HAS2 gene in the nucleus. Here, we focused on the direct 
regulation by SMILR in the cytoplasm and find effects mediated by a distinct proliferative network, but we 
cannot rule out a downstream effect in the nucleus due to SMILR manipulation, or indeed a further 
proliferative effect mediated selectively in the nucleus by SMILR by an independent mechanism. In 
particular, we noticed the presence of histone mRNAs among the dysregulated genes from the RNAseq 
data. Although histone mRNAs are not within the list of SMILR predicted targets, the observed level change 
at the RNA level could lead to protein level changes and subsequent transcriptional changes.  
 
The up- or downregulation of the SMILR-axis and its consequential effects on vSMC proliferation 
could influence numerous cardiovascular diseases. This was apparent in the ex vivo vein graft model in this 
study and suggests that this can influence neointimal hyperplasia and hence the long term success of 
revascularisation of vein graft after coronary artery bypass surgery. Interestingly we found a similar role 
for SMILR in HCASMCs and may therefore also be involved in atherosclerosis. However targeting of 
SMILR may not be beneficial due to the potential reduction in stability and formation of a fibrous cap.  
Further studies are however required to fully understand the influence of the SMILR-axis with respect to 
SMC proliferation in the atherosclerotic environment and hence the susceptibility to plaque rupture and 
ultimately myocardial infarction and stroke. 
 
Significantly, within a clinically-amenable timeframe, siRNA-based gene therapy targeting SMILR 
is sufficient to markedly reduce proliferation in the ex vivo vein model. This excitingly provides a vSMC-
specific target, which reduces the possibility of off-target effects in the remainder of the vessel wall, i.e. 
inhibited re-endothelialisation. This strongly suggests that such an intervention may reduce vein graft 
failure rates. Although our studies only show successful knockdown with siRNA for a limited time frame, 
whether this is sufficient to maintain a long term anti-proliferative effect is something that requires further 
studies. Nonetheless, other routes of SMILR-targeting gene therapy may be required for maximum longevity 
such as LNA-GapmeR antisense oligonucleotides (ASOs) 13. However, ASOs target both nuclear and 
cytoplasmic fractions of a cell whereas siSMILR only has a cytoplasmic effect (Supplemental figure 6). 
Accordingly, the subsequent effects of ASOs knockdown of SMILR in the nuclear fraction must be studied 
to ensure no detrimental effects. 
 
We demonstrate that SMILR is a vSMC-enriched lncRNA, essential in the control of cell-cycle 
through binding of CENPF mRNA and STAU1. Our studies provide early but compelling evidence that 
SMILR is an exciting and novel target in the treatment of aberrant growth of vascular smooth muscle cells, 
with the potential to significantly reduce the rate of vein graft failure. 
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FIGURE LEGENDS 
 
Figure 1. Transcriptomics identifies a cell cycle-associated network targeted by SMILR in 
proliferative vSMCs. 
(A) Schematic of experimental design for SMILR knockdown and overexpression using dsiRNA and 
lentivirus (LNT), respectively. MOI = multiplicity of infection. (B) Validation of SMILR knockdown and 
overexpression via qRT-PCR of 3 technical replicates used for RNAseq from one patient sample. (C) Venn 
diagrams illustrating the number of genes dysregulated by SMILR knockdown and overexpression. (D) 
Heatmap of all overlapping 68 significant changes observed upon SMILR depletion and overexpression. 
Fold change calculated compared to the average FPKM in the control (CONT) samples. (E)  Gene Ontology 
(GO) terms for the SMILR-regulated gene cohort. (F) Protein network of 40 proliferative and cell-cycle 
associated genes found to be dysregulated with SMILR depletion and overexpression. (G,H) Further 
validation by qRT-PCR of the top 20 identified dysregulated proliferative and cell-cycle associated genes 
with siRNA Control (siCtrl) versus siSMILR and control LNT (Null LNT) versus SMILR LNT. * = p < 
0.05, by Iman and Conover non parametric ranked paired student’s t-test of deltaCT values between gene 
of interest and the housekeeper gene UBC, n = 3 biological replicates. 
 
Figure 2. SMILR manipulation regulates the cell cycle of vSMC. 
(A) Schematic of FUCCI viral analysis. (B) Flow cytometric analysis tracking cell cycle changes indicated 
by colour changes of the FUCCI viruses. (C) Bar chart representing average changes in the % of cells in 
each stage of the cell cycle. Repeated measures ANOVA for * p<0.05, Iman and Conover ranked non 
parametric analysis followed by one way ANOVA, n = 3 biological replicates. (D) Fluorescent Microscopy 
of HSVSMCs infected with the FUCCI viral system. Scale bars at 50 µm. Red arrows indicate binucleated 
cells. (E) Schematic of characterisation method of binucleated cells. (F) Fluorescent images of HSVSMCs 
stained with DAPI and phalloidin. Scale bars at 50 µm. Red arrows indicate binucleated cells. (G) Bar chart 
representing the % of total cells that were binucleated. * = p < 0.05, Iman and Conover ranked non 
parametric analysis followed by one way ANOVA vs IL1α/PDGF-ββ treatment alone (I+P); + = p < 0.05 
vs siControls, n = 3 biological replicates. (H) Bar chart representing caspase-3 activity in HSVSMCs 
cultured with siRNA or hydrogen peroxide as a positive control. Caspase activity measured by OD405. n 
= 3 biological replicates, vs I+P treatment. ns = not significant.  
 
Figure 3. RNA: RNA analysis reveal a SMILR: CENPF interaction. 
(A) Schematic of DNA antisense biotinylated probes site for SMILR and GFP and the experimental design 
of RNA: RNA pulldowns. (B) Bar charts representing relative enrichments of SMILR, CENPF, and MKI67 
in SMILR even and odd pulldowns versus the GFP control pulldown. Each even and odd SMILR probe 
pulldown was performed once across two independent biological replicates. Effects of (C) SMILR 
knockdown and (D) SMILR overexpression on CENPF mRNA. ** = p < 0.05 Iman and Conover non 
parametric ranked analysis followed by students t-test, n = 3 biological replicates. (E) Representative FACs 
histogram plots depicting EdU uptake in siCtrl and siCENPF treated HSVSMCs. Gate represents EdU+ 
cells. (F) Bar chart showing mean changes of EdU incorporation in siCtrl and siCENPF treated HSVSMCs. 
Iman and Conover ranked non parametric analysis followed by t-test, n=3 biological replicates. * = p < 
0.05. (G) Fluorescent images of HSVSMCs stained with DAPI and phalloidin. Scale bar represents 50 µm. 
Red arrows indicate binucleated cells. (H) Bar chart representing the % of total cells that were binucleated. 
Iman and Conover ranked non parametric analysis followed by students t-test * = p < 0.05vs siCtrl, n = 3 
biological replicates. (I) The effects of CENPF knockdown on mitotic associated genes compared to effects 
observed with knockdown of SMILR, * = p < 0.05, by Iman and Conover ranked non parametric analysis 
followed by paired t-test, n = 4 biological replicates. 
 
Figure 4. STAU1 degrades the SMILR: CENPF interaction to mediate vSMC proliferation. 
(A) Schematic showing methodology of biotinylated SMILR-pulldowns. (B) Mass spectrometry identified 
14-enriched SMILR-binding proteins. Staufen1 (STAU1) was specifically enriched in the SMILR pulldown 
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with 11-unique peptides detected. (C) Anti-STAU1 pulldowns confirming interaction with SMILR and 
CENPF; * = p < 0.05, by Iman and Conover ranked non parametric analysis followed by t-test, n = 3 
pulldowns from 3 independent patient samples. (D) Relative quantification of STAU1, SMILR, and CENPF 
expression with SiSTAU1 at 10nM. * = p < 0.05, by Iman and Conover ranked non parametric analysis 
followed by t-test, n = 3 biological replicates. (E) The effects of STAU1 knockdown on the top 20 
downregulated cell-cycle associated genes regulated by SMILR, * = p< 0.05, by Iman and Conover ranked 
non parametric analysis followed by t-test, n = 3 biological replicates. (F) RNA fluorescence in situ 
hybridization (FISH) for SMILR (red) and CENPF (green) in stimulated vSMCs under control, siSMILR, 
siCENPF, and siSTAU1 conditions. Scale bar represents 20 µm. Yellow arrows show some co-localisation 
events.  
 
Figure 5. SMILR and the targeted cell cycle network are activated in atherosclerosis  
(A) Ex vivo 18F imaging of unstable versus stable plaques. (B) Principal Component Analysis (PCA) of 
the RNAseq of the stable and unstable samples.  (C) Relative FPKMs of protein coding genes linked with 
plaque instability, including those associated with inflammation and calcification. (D) Representative 
images of in situ detection of SMILR in plaques obtained from the carotid artery derived from symptomatic 
patients at carotid endarterectomy (n = 5 biological replicates per plaque type, replicates in Supplemental 
Figure 12). SMILR is visualised using NBT/BCIP (purple) at varying intensities across plaques exhibiting 
either intraplaque haemorrhage or thick fibrous cap. Nuclei are stained with fast red. L, indicates arterial 
lumen; NC, lipid core; scale bar represents 200 μm (E) SMILR enrichment in STAU1 pulldowns in whole 
carotid plaques, n = 6, ** = p < 0.01, by paired student t-test with paired experiments matched by colour. 
Protein network (F) and heatmap (G) of the 34 proliferative and cell-cycle associated genes found to be 
dysregulated with SMILR manipulation and unregulated in unstable plaques.  
 
Figure 6. Role of SMILR in human coronary artery smooth muscle cells. 
(A) Representative FACs histogram plots depicting EdU uptake in 0.2% and I+P treated HCASMCs. Gate 
represents EdU+ cells. (B) Bar chart showing mean changes of EdU incorporation in 0.2% and I+P 
conditions. Iman and Conover ranked non parametric analysis followed by t-test, n=3 biological replicates. 
* = p < 0.05. Bar charts showing relative expression of (C) SMILR and (D) CENPF, MKI67, AURKB, and 
CDC20 by qRT-PCR in 0.2% and I+P stimulated HCASMCs. Iman and Conover ranked non parametric 
analysis followed by t-test, n=3 biological replicates. ** = p < 0.05. (E) Representative FACs histogram 
plots depicting EdU uptake in siCtrl, siSMILR, and siCENPF treated HCASMCs. Gate represents EdU+ 
cells. (F) Bar chart showing mean changes of EdU incorporation in siCtrl, siSMILR, and siCENPF treated 
cells. Iman and Conover ranked non parametric analysis followed by t-test, n=3 biological replicates, * = p 
< 0.05. 
 
Figure 7. SMILR modulates the proliferation of the ex vivo human saphenous vein organ culture. (A) 
Graphical representation of ex vivo HSV proliferation model. (B) Quantification of EdU +ve nuclei in the 
media of HSV in culture expressed as % of EdU +ve/DAPI +ve nuclei. # = p < 0.05, * = p < 0.0,. * versus 
Day 0, # versus Day 7 using Iman and Conover ranked non parametric analysis followed by one-way 
ANOVA (n=3 biological replicates per time point). (C) Representative images of HSV in culture stained 
for EdU (green) and with DAPI (blue) at day 0, 7, and 14 (n = 3 biological replicates per time point). SMILR 
(D) and CENPF (E) expression determined by qRT-PCR analysis at day 0, 7 and 14. * P<0.05 and *** 
P<0.001 vs day 0 analysed by one way ANOVA (n=7).  (F) Left: Graphical representation of the model of 
HSV siSMILR intervention; Right: Representative image of Cy3-labeled SMILR siRNA localization in 
HSV at 3 days post-siSMILR intervention; the section is co-stained with DAPI (blue) and for α-smooth 
muscle actin (αSMA, green) at 60x magnification. Relative quantification of (G) SMILR, (H) CENPF, and 
(I) MKI67 expression in HSV after siSMILR intervention at day 7 normalized to UBC. * = p < 0.05, ** = 
p < 0.01 by paired two-tailed Student’s t-test, n = 5 biological replicates. (J) Representative images of HSV 
post-siSMILR intervention stained for EdU (green) and with DAPI (blue). (K) Mean ± SEM of EdU +ve 
nuclei in the media of HSV after siSMILR intervention expressed as % of EdU +ve/DAPI +ve nuclei.  (n 
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= 3 biological replicates). Values are * = p < 0.05; vs siCtrl using Iman and Conover ranked non parametric 
analysis followed by student’s t-test. 
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NOVELTY AND SIGNIFICANCE 
 
 
What Is Known? 
 
 Like other non-coding RNA, long non-coding RNA (lncRNA) can regulate key aspects of smooth 
muscle cell function. 
 
 LncRNA SMILR regulates SMC proliferation via an unknown mechanism.  
 
What New Information Does This Article Contribute? 
 
 LncRNA SMILR regulates a network of cell cycle-associated mRNAs in vascular smooth muscle 
cells.  
 
 LncRNA SMILR binds directly to the mitotic cell regulator centromere protein F (CENPF) 
mRNA.  
 
 Inhibition of SMILR by RNA interference blocks vascular smooth muscle cell proliferation in 
intact saphenous vein.  
 
 
VSMC proliferation has been recognised as central to the pathology of many major forms of vascular 
disease including intimal hyperplasia associated with vein graft failure. Previously, RNA-sequencing 
identified SMILR as a novel intergenic lncRNA activated by vSMC proliferation. Understanding the 
molecular mechanisms governing the mode of action of SMILR is an important next step. Specific 
modulation of SMILR levels revealed its role in regulating a mitotic mRNA network and more specifically 
a central role for binding to the cell cycle associated CENPF mRNA. Specific knockdown of SMILR 
resulted in the accumulation of binucleated cells and reduced proliferation and was phenotypically copied 
by silencing of CENPF.  Further, we show that SMILR binds the RNA-binding protein Stau1 which may 
aid in the regulation of cell cycle.  Finally, SMILR inhibition in whole vein segments resulted in the 
reduction of SMC proliferation through modulation of the key cell cycle network. Our findings provide 
compelling evidence that SMILR is a novel target in the treatment of aberrant growth of vascular smooth 
muscle cells.  
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